Abiopharma

New Form 8-K - Amylyx Pharmaceuticals, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104546 Size: 377 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Monte Rosa Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104545 Size: 472 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Riverstone Reports A Net Profit Of RM101.8 Million In 1HFY25

Financial Statements And Related Announcement :: Second Quarter And/ Or Half Yearly Results

Financial Statements and Related Announcement: Second Quarter and/ or Half Yearly Results

New Form 8-K - INSMED Inc Filed: 2025-08-07 AccNo: 0001140361-25-029343 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Black Diamond Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001701541-25-000029 Size: 229 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Avalo Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001628280-25-038570 Size: 446 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

XORTX Provides Corporate Update and PlannedActivities for 2025 / 2026

Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates